The Study On Clinical Effect And Influence On FasL With Ziqian Compound In Chronic Immune Thrombocytopenia

Objective:To observe the effects of ZI QIAN compound on the treatment of chronic immune thrombocytopenia (CITP) through the changes of the total symptom score,PLT count and peripheral blood death factor ligand Fasl. To discuss the mechanism of CITP and the effect of ZI QIAN compound to CITP and provide the theoretical basis for the further clinical application of ZI QIAN compound.Methods:30 patients with CITP were treated with the ZI QIAN compound for two courses which contain two months, Evaluate the effects of ZI QIAN compound through the comparative analysis of changes of the total symptom score-, PLT count and peripheral blood death factor ligand Fasl.Results:1.the total effective rate of ZI QIAN compound to the CITP patients is 86.67%. Statistical analysis of the total symptom score and the clinical results of PLT count showed that the results was statistically significant (P<0.01).2.Compared with the patients with CITP before the treatment of ZI QIAN compound and control groups.the level of Fasl of the patients after the treatment was decreased significantly (P<0.01).Conclusions:1.ZI QIAN compound can decrease the total symptom score of the patients with CITP.2.The PLT count of the patients with CITP after the treatment was increased but the level of the Fasl was decreased.3.The high expression of Fasl of the patients with CITP may affect the cellular immune links and medicate the abnormal apoptosis of T lymphocytes and lead to CITP.4.ZI QIAN compound may maintain the normal T lymphocyte apoptosis to play a role in the treatment of CITP through decreasing the level of Fasl of the patients with CITP.